Yixin Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yixin Cheng has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Chun Wu
State Key Laboratory of Oncology in South China 4 Department of Nasopharyngeal Carcinoma Guangdong Provincial Clinical Research Center for Cancer Guangzhou, China
79 shared publications - Xin Hong
Southern University of Science and Technology 1 Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine Shenzhen, China
79 shared publications - Xuefei Liu
Southern University of Science and Technology 1 Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine Shenzhen, China
79 shared publications - Feiqiu Wen
Southern University of Science and Technology 2 Department of Hematology and Oncology, Shenzhen Children’s Hospital and School of Medicine Shenzhen, China
78 shared publications - Guanyin Huang
Southern University of Science and Technology 1 Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine Shenzhen, China
78 shared publications - Jingru Lian
Southern University of Science and Technology 1 Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine Shenzhen, China
78 shared publications
Latest Publications
- 12 November 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- p. OF1-OF15
The PDGFB–DDX5 Axis Contributes to Breast Cancer Radioresistance through HR-Associated DNA Repair
Radioresistance remains a major barrier to effective breast cancer treatment, yet the molecular programs underlying acquired resistance remain incompletely understood. By establishing and characterizing radioresistant (RR) breast cancer cell models across multiple molecular subtypes, we revealed enhanced DNA repair capacity and epithelial–mesenchymal transition features in resistant cells. Transcriptomic profiling and functional validation identified platelet-derived growth factor (PDGF) B as a key regulator of radioresistance. High PDGFB expression was associated with adverse outcomes across independent breast cancer cohorts, including a radiotherapy-treated subgroup. Mechanistically, PDGFB associated with DEAD-box RNA helicase 5 (DDX5) and stabilized DDX5 by limiting its ubiquitin–proteasome–mediated degradation. PDGFB depletion impaired homologous recombination (HR) efficiency, delayed DNA damage resolution, reduced RAD51 foci formation, and resensitized RR cells to irradiation in vitro and in vivo. Conversely, DDX5 overexpression partially restored HR signaling, DNA damage resolution, and clonogenic survival in PDGFB-depleted cells. These findings uncovered a PDGFB–DDX5 regulatory axis that preferentially targets HR-associated DNA repair and contributes to breast cancer radioresistance. Implications: This study demonstrates the PDGFB–DDX5 axis as a crucial mechanism contributing to radioresistance by preferentially affecting HR-mediated DNA damage repair, which can be therapeutically explored for overcoming radioresistance in breast cancer.
- 12 November 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- p. OF1-OF15
The PDGFB–DDX5 Axis Contributes to Breast Cancer Radioresistance through HR-Associated DNA Repair
Radioresistance remains a major barrier to effective breast cancer treatment, yet the molecular programs underlying acquired resistance remain incompletely understood. By establishing and characterizing radioresistant (RR) breast cancer cell models across multiple molecular subtypes, we revealed enhanced DNA repair capacity and epithelial–mesenchymal transition features in resistant cells. Transcriptomic profiling and functional validation identified platelet-derived growth factor (PDGF) B as a key regulator of radioresistance. High PDGFB expression was associated with adverse outcomes across independent breast cancer cohorts, including a radiotherapy-treated subgroup. Mechanistically, PDGFB associated with DEAD-box RNA helicase 5 (DDX5) and stabilized DDX5 by limiting its ubiquitin–proteasome–mediated degradation. PDGFB depletion impaired homologous recombination (HR) efficiency, delayed DNA damage resolution, reduced RAD51 foci formation, and resensitized RR cells to irradiation in vitro and in vivo. Conversely, DDX5 overexpression partially restored HR signaling, DNA damage resolution, and clonogenic survival in PDGFB-depleted cells. These findings uncovered a PDGFB–DDX5 regulatory axis that preferentially targets HR-associated DNA repair and contributes to breast cancer radioresistance. Implications: This study demonstrates the PDGFB–DDX5 axis as a crucial mechanism contributing to radioresistance by preferentially affecting HR-mediated DNA damage repair, which can be therapeutically explored for overcoming radioresistance in breast cancer.
- Open Access
- 13 October 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (10) , e70852
Radiation‐induced AXL upregulation in CCR2 + monocytes promotes cardiac fibrosis
Background: Thoracic radiotherapy can cause delayed cardiac fibrosis, but the immune mechanisms linking radiation injury to fibroblast activation remain unclear. We investigated whether CCR2 + monocytes contribute to radiation‐induced cardiac fibrosis and whether AXL regulates their fibroblast‐activating activity. Methods and materials: C57BL/6 mice received 20 Gy whole‐thorax irradiation, and remodelling was assessed from IR_D0 to IR_D60. Bulk RNA sequencing was integrated with single‐cell datasets and CIBERSORTx deconvolution, lineage tracing, and tissue staining. CCR2 + monocyte function was examined by CCR2 neutralisation, and circulating CCR2 + Ly6Cʰ i monocytes were quantified by flow cytometry. AXL was investigated using inducible myeloid Axl deletion and bemcentinib (R428). MAPK signalling was assessed by transcriptomic analysis and immunoblotting of sorted CCR2 + Ly6Cʰ i monocytes. Conditioned medium from sorted monocytes after Axl deletion, AXL inhibition with R428, or MEK1/2 inhibition with U0126 was applied to cardiac fibroblasts. Results: Cardiac fibrosis was established by IR_D30, while leukocyte infiltration and apoptotic signals remained above baseline. Transcriptomic analyses and lineage tracing showed increased cardiac accumulation of CCR2 + monocytes. CCR2 neutralisation reduced circulating CCR2 + Ly6Cʰ i monocytes and attenuated interstitial collagen deposition and fibrotic marker expression. Axl was enriched in the CCR2 + monocyte compartment. Myeloid Axl deletion and R428 reduced cardiac fibrosis. Axl deletion suppressed MAPK‐related transcriptional programs, whereas genetic or pharmacological AXL targeting reduced MEK and ERK phosphorylation in sorted monocytes. Conditioned medium from IR_D30 monocytes induced COL1A1 and α‐SMA expression in fibroblasts, and this effect was reduced by Axl deletion, R428, or U0126 treatment of donor monocytes. Conclusions: AXL signalling contributes to the fibroblast‐activating paracrine activity of cardiac CCR2 + monocytes after irradiation, at least in part through MEK/ERK signalling. Key points: Radiation exposure induces cardiac fibrosis through immunestromal interactions. CCR2 + monocytes promote fibroblast activation during radiation-induced cardiac fibrosis. AXL regulates monocyte‐mediated fibroblast activation through MEK/ERK signaling. Targeting the AXL‐MEK/ERK pathway may provide a potential strategy for preventing radiation‐induced cardiac fibrosis.
- 13 October 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (10) , e70852
Open AccessRadiation‐induced AXL upregulation in CCR2 + monocytes promotes cardiac fibrosis
Background: Thoracic radiotherapy can cause delayed cardiac fibrosis, but the immune mechanisms linking radiation injury to fibroblast activation remain unclear. We investigated whether CCR2 + monocytes contribute to radiation‐induced cardiac fibrosis and whether AXL regulates their fibroblast‐activating activity. Methods and materials: C57BL/6 mice received 20 Gy whole‐thorax irradiation, and remodelling was assessed from IR_D0 to IR_D60. Bulk RNA sequencing was integrated with single‐cell datasets and CIBERSORTx deconvolution, lineage tracing, and tissue staining. CCR2 + monocyte function was examined by CCR2 neutralisation, and circulating CCR2 + Ly6Cʰ i monocytes were quantified by flow cytometry. AXL was investigated using inducible myeloid Axl deletion and bemcentinib (R428). MAPK signalling was assessed by transcriptomic analysis and immunoblotting of sorted CCR2 + Ly6Cʰ i monocytes. Conditioned medium from sorted monocytes after Axl deletion, AXL inhibition with R428, or MEK1/2 inhibition with U0126 was applied to cardiac fibroblasts. Results: Cardiac fibrosis was established by IR_D30, while leukocyte infiltration and apoptotic signals remained above baseline. Transcriptomic analyses and lineage tracing showed increased cardiac accumulation of CCR2 + monocytes. CCR2 neutralisation reduced circulating CCR2 + Ly6Cʰ i monocytes and attenuated interstitial collagen deposition and fibrotic marker expression. Axl was enriched in the CCR2 + monocyte compartment. Myeloid Axl deletion and R428 reduced cardiac fibrosis. Axl deletion suppressed MAPK‐related transcriptional programs, whereas genetic or pharmacological AXL targeting reduced MEK and ERK phosphorylation in sorted monocytes. Conditioned medium from IR_D30 monocytes induced COL1A1 and α‐SMA expression in fibroblasts, and this effect was reduced by Axl deletion, R428, or U0126 treatment of donor monocytes. Conclusions: AXL signalling contributes to the fibroblast‐activating paracrine activity of cardiac CCR2 + monocytes after irradiation, at least in part through MEK/ERK signalling. Key points: Radiation exposure induces cardiac fibrosis through immunestromal interactions. CCR2 + monocytes promote fibroblast activation during radiation-induced cardiac fibrosis. AXL regulates monocyte‐mediated fibroblast activation through MEK/ERK signaling. Targeting the AXL‐MEK/ERK pathway may provide a potential strategy for preventing radiation‐induced cardiac fibrosis.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S11. Metastatic lesions in vivo.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S11. Metastatic lesions in vivo.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S1. Comprehensive characterization of CD4+ T cells in CRC.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S1. Comprehensive characterization of CD4+ T cells in CRC.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Information of published scRNA-seq datasets used in Pan_CD4 single-cell atlas in this study.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Information of published scRNA-seq datasets used in Pan_CD4 single-cell atlas in this study.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S2. Comprehensive characterization of CD4+ T cells in Pan_cancer.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S2. Comprehensive characterization of CD4+ T cells in Pan_cancer.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S8. NMB + CXCL13+CD4+ T cells induce tumor cell malignancy.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S8. NMB + CXCL13+CD4+ T cells induce tumor cell malignancy.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S9. NPSR1+ senescent tumor cells recruit and disrupt endothelial cells.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S9. NPSR1+ senescent tumor cells recruit and disrupt endothelial cells.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S4. NMB expression correlates with poor CRC patient prognosis but is independent of ICI response.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
Supplementary Figure S4. NMB expression correlates with poor CRC patient prognosis but is independent of ICI response.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
The specially expressed genes in each subclusters of CRC CXCL13+CD4+ T cell.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy
The specially expressed genes in each subclusters of CRC CXCL13+CD4+ T cell.